Candel Therapeutics (CADL) Non-Current Deffered Revenue (2020 - 2025)

Candel Therapeutics has disclosed Non-Current Deffered Revenue across 5 years of filings, most recently posting $89000.0 for Q4 2025.

• Non-Current Deffered Revenue for Q4 2025 came in at $89000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $89000.0 (changed N/A YoY), and the FY2025 annual result was $89000.0, changed N/A from the prior year.
• Non-Current Deffered Revenue came in at $89000.0 for Q4 2025 at Candel Therapeutics, down from $108000.0 in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $894000.0 in Q4 2021 to a low of $31000.0 in Q3 2021.
• The 4-year median for Non-Current Deffered Revenue is $126000.0 (2023), against an average of $262375.0.
• Across the five-year window, Non-Current Deffered Revenue soared 615.2% in 2021 and sank 83.89% in 2022, its largest moves.
• Candel Therapeutics' Non-Current Deffered Revenue stood at $894000.0 in 2021, then tumbled by 83.89% to $144000.0 in 2022, then declined by 25.0% to $108000.0 in 2023, then fell by 17.59% to $89000.0 in 2025.
• The last three Non-Current Deffered Revenue figures came in at $89000.0 (Q4 2025), $108000.0 (Q3 2023), and $120000.0 (Q2 2023), per Business Quant data.